Stockreport

Novo Nordisk hopes to launch experimental obesity drug this decade [Globe and Mail, The (Toronto, Canada)]

Catalent, Inc.  (CTLT) 
Last catalent, inc. earnings: 2/3 07:30 am Check Earnings Report
US:NYSE Investor Relations: investor.catalent.com
PDF It expects both new experimental obesity drugs cagrisema and amycretin to lead to greater weight loss than its hugely popular Wegovy. They would also likely have simila [Read more]